

## AARC Clinical Practice Guideline: Transcutaneous Monitoring of Carbon Dioxide and Oxygen: 2012

Ruben D Restrepo MD RRT FAARC, Keith R Hirst MSc RRT-NPS,  
Leonard Wittnebel MSIS RRT, and Richard Wettstein MMEd RRT

An electronic literature search for articles published between January 1990 and September 2011 was conducted by using the PubMed, CINAHL, SCOPUS, and Cochrane Library databases. The update of this clinical practice guideline is the result of reviewing a total of 124 articles: 3 randomized controlled trials, 103 prospective trials, 1 retrospective study, 3 case studies, 11 review articles, 2 surveys and 1 consensus paper on transcutaneous monitoring (TCM) for  $P_{tcO_2}$  and  $P_{tcCO_2}$ . The following recommendations are made following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria: (1) Although  $P_{tcCO_2}$  has a good correlation with  $P_{aCO_2}$  and is a reliable method to evaluate plasma  $CO_2$  levels, it is recommended that arterial blood gas values be compared to transcutaneous readings taken at the time of arterial sampling, in order to verify the transcutaneous values, and periodically as dictated by the patient's clinical condition. (2) It is suggested that  $P_{tcCO_2}$  may be used in clinical settings where monitoring the adequacy of ventilation is indicated. (3) It is suggested that  $P_{tcO_2}$  and  $P_{tcCO_2}$  may be used in determining the adequacy of tissue perfusion and monitoring of reperfusion. (4) It is suggested that TCM should be avoided in the presence of increased thickness or edema of the skin and/or subcutaneous tissue where the sensor is applied. (5) It is recommended that sites used for a TCM be changed as often as necessary and that they be alternated and observed to avoid thermal injury. Manufacturer recommendations should be followed. Key words: *clinical practice guidelines; hyperbaric oxygen therapy; reperfusion; transcutaneous monitoring; transcutaneous carbon dioxide; transcutaneous carbon dioxide monitoring; transcutaneous oxygen; transcutaneous oxygen monitoring.* [Respir Care 2012; 57(11):1955–1962. © 2012 Daedalus Enterprises]

### TCM 1.0 INTRODUCTION

Since pulse oximetry is considered the standard of care for noninvasive monitoring of oxygen levels, routine transcutaneous monitoring (TCM) of oxygen pressure ( $P_{tcO_2}$ ) has fallen out of favor. While some studies in infants<sup>1–3</sup> have shown that TCM of  $P_{O_2}$  may be more reliable than

monitoring oxygenation via  $S_{pO_2}$ , most of the studies are focused on TCM of carbon dioxide pressure ( $P_{tcCO_2}$ ), which is considered an accurate and clinically acceptable estimate of the  $P_{aCO_2}$ .<sup>4–13</sup>

### TCM 2.0 DESCRIPTION/DEFINITION

A transcutaneous (TC) monitor measures the skin-surface  $P_{O_2}$  and  $P_{CO_2}$  to provide an estimate of the  $P_{aO_2}$  and

---

Dr Restrepo, Mr Wittnebel, and Mr Wettstein are affiliated with the Department of Respiratory Care, The University of Texas Health Sciences Center at San Antonio, San Antonio, Texas. Mr Hirst is affiliated with the Department of Respiratory Care, Rush University, Chicago, Illinois.

Dr Restrepo has disclosed relationships with Oridion and Teleflex. The other authors have disclosed no conflicts of interest.

Correspondence: Ruben D Restrepo MD RRT FAARC, Department of Respiratory Care, The University of Texas Health Science Center at San Antonio, MSC 6248, San Antonio TX 78229. E-mail: restrep0@uthscsa.edu.

DOI: 10.4187/respcare.02011

$P_{aCO_2}$ . The measurements obtained include  $P_{tcO_2}$  and  $P_{tcCO_2}$ . The TC monitor device induces hyperperfusion of the capillaries by increasing the local temperature of the skin at the sensor site. The externally applied heat alters the solubility of  $CO_2$  in the blood and increases the metabolic rate of the skin by approximately 4–5% for every degree Celsius, resulting in local production of  $CO_2$ .<sup>14</sup> The sensor, usually a Severinghaus electrode, will calculate the  $P_{CO_2}$  electrochemically, usually by a change in pH of an electrolyte solution. Additionally, a temperature correction is used to address the epithelial  $CO_2$  produced by heating the skin.<sup>1,15–20</sup> A Clark electrode, which is composed of a platinum cathode and silver anode, measures the  $P_{O_2}$ .<sup>21</sup>

Each manufacturer's calibration protocol for the TC monitor sensor should be followed. After the sensor is calibrated, the skin must be cleaned of all oils, soaps, and dead skin. Once the site is cleaned, then a sensor fixation ring should be placed in a highly vascularized area. The preferred location to obtain TC measurements in neonates and small pediatric patients is the upper chest. Alternative sites may be the lateral side of the abdomen, chest, buttock, inside of the upper thigh, forearm, the zygomatic bone, the ear lobe, cheeks, or the forehead.<sup>22–26</sup> In order to achieve accurate  $P_{tcO_2}$  the skin probe temperature must be 44°C, which may lead to injury or burning of the skin, particularly in patients with thin or damaged skin.<sup>27</sup> By contrast, monitoring of the  $P_{tcCO_2}$  is reliable with skin temperature even as low as 37°C.<sup>1,28</sup> Most TC monitors allow the reduction of the probe temperature to minimize the risk of thermal injury.<sup>29</sup> Correlation with arterial blood gases is recommended to ensure accuracy of the values obtained by TC monitor.<sup>29</sup> When monitoring  $P_{tcCO_2}$  only, use of lower skin probe temperatures increases the systematic overriding of TC measurement and may allow for longer periods of contact time between the skin and the sensor, for up to 8–12 hours. This option may be especially important for neonatal population compliance with the minimal handling approach promoted in their care. However, changing sites as often as every 2 hours may be necessary in small premature neonates to avoid thermal injury.

After the fixation device is in place, 1–2 drops of either contact gel or normal saline should be placed inside the ring. This improves the accuracy of the sensor and makes the diffusion of gases more efficient. The sensor is then placed into the ring and usually snaps into place. The ring must create enough of a seal to prevent leaks or formation of air bubbles, as ambient air reaching the sensor affects measured values.

### TCM 3.0 SETTING

TCM may be performed by trained personnel in a variety of settings that include, but are not limited to hospitals, extended care facilities, and patient transport.<sup>20,22,30</sup> It

is utilized in the following specific clinical settings to determine the presence of hypoventilation or respiratory depression:

- 3.1** Mechanical ventilation, including conventional modes of ventilation,<sup>31–33</sup> high-frequency ventilation,<sup>27,34</sup> steady state high frequency jet ventilation,<sup>35</sup> and noninvasive ventilation.<sup>34–39</sup>
- 3.2** Bronchoscopies or procedures requiring sedation<sup>23,40–45</sup> or patient-controlled analgesia<sup>46–48</sup>
- 3.2.1** Prolonged laparoscopic surgery procedures<sup>49</sup>
- 3.3** Sleep studies<sup>50–55</sup>
  - 3.3.1**  $P_{tcO_2}$  may have an increased role in detecting sleep hypoventilation and assessing the efficacy of treatment of sleep disorders.<sup>56</sup>
- 3.4** Pulmonary function studies, including stress testing and bronchoprovocation<sup>12,39,57–59</sup>
- 3.5** Trending  $HCO_3^-$  in diabetic ketoacidosis<sup>60</sup>
- 3.6** Apnea testing<sup>61</sup>
- 3.7** Transportation of a patient<sup>9,29</sup>
- 3.8** Evaluation of tissue perfusion<sup>27,43,62–67</sup>
- 3.9** Evaluation of postoperative hypercarbia<sup>9,68,69</sup>
- 3.10** Evaluation of hyperventilation during phonation of patients with vocal cord disorders<sup>70,71</sup>
- 3.11** Titration of long-term oxygen therapy<sup>72</sup>

### TCM 4.0 INDICATIONS

The use of TCM is indicated in patients who either lack arterial access or have the need for continuous monitoring of oxygen and carbon dioxide with minimal blood draws.<sup>60</sup> TCM allows the assessment of:

- 4.1** adequacy of oxygenation and/or ventilation<sup>2,9,10,13,22,25,29,30,37,50,73–76</sup>
- 4.2** response to diagnostic and therapeutic interventions, as evidenced by  $P_{tcO_2}$  and/or  $P_{tcCO_2}$  values<sup>2,22,29,30,37,38,64,67,74,77</sup>
  - 4.2.1** Weaning and extubation decisions may be made based on  $P_{tcCO_2}$  measurement alone.<sup>78,79</sup>
- 4.3** TC oxygen index ( $P_{tcO_2}/F_{IO_2}$ ), which can be used as an early marker of hypoperfusion and mortality<sup>62,63</sup>
  - 4.3.1** A ratio less than 200 should prompt evaluation and intervention.<sup>61</sup>
- 4.4** tissue perfusion status and revascularization in wound care and peripheral arterial occlusive disease<sup>80</sup>
  - 4.4.1**  $P_{tcO_2}$  is used in wound care and hyperbaric oxygen therapy as an effective tool to monitor critical limb ischemia.
    - 4.4.1.1** A  $P_{tcO_2}$  on the affected limb should be maintained between 30–40 mm Hg to maintain adequate perfusion. A  $P_{tcO_2}$  less than 30 mm Hg may indicate poor perfusion to that limb, and a  $P_{tcO_2}$  less than 10 mm Hg is considered incompatible with spontaneous healing process.<sup>81,82</sup>

**4.4.1.2**  $P_{tcO_2}$  is useful in the determination of optimal amputation level. A  $P_{tcO_2}$  of 30 mm Hg is considered the critical dividing value that separates successful from unsuccessful amputation stump healing.

**4.5** monitoring response to therapy in patients with diabetic ketoacidosis, as  $P_{tcCO_2}$  correlates with serum  $HCO_3^-$  levels<sup>59</sup>

## TCM 5.0 CONTRAINDICATIONS

There are no documented absolute contraindications for use of TCM. In patients with poor skin integrity and/or adhesive allergy, alternative monitoring devices to TCM should be considered.<sup>29</sup>

## TCM 6.0 HAZARDS/COMPLICATIONS

$P_{tcO_2}$  and/or  $P_{tcCO_2}$  monitoring is considered a safe procedure. The most common hazards and complications of TCM are:

**6.1** Misinterpretation of falsely elevated or decreased levels of  $O_2$  and  $CO_2$  that may lead to inappropriate treatment of the patient.<sup>75,83,84</sup>  $P_{tcO_2}$  underestimates  $P_{aO_2}$  and  $P_{tcCO_2}$  overestimates  $P_{aCO_2}$ . While some manufacturers have incorporated correction factors into the device software, what TCM really measures is skin  $P_{O_2}$  and  $P_{CO_2}$ , not  $P_{aO_2}$  and  $P_{aCO_2}$  per se.<sup>75,83,84</sup>

**6.2** Thermal injury may occur at the sensor site (eg, erythema, blisters, burns, skin tears).<sup>10,16,22,85-87</sup>

## TCM 7.0 DEVICE LIMITATIONS/VALIDATION OF RESULTS

$P_{tcO_2}$  is an indirect measurement of  $P_{aO_2}$  and does not reflect oxygen delivery or oxygen content. Complete assessment of oxygen delivery requires knowledge of hemoglobin saturation and cardiac output.  $P_{tcCO_2}$  is an indirect measurement of  $P_{aCO_2}$ , but knowledge of delivery and content is not necessary to use  $P_{tcCO_2}$  for assessment of ventilation.

Factors that may affect readings, limit precision, or limit the performance or application of a TC monitor include:

### 7.1 Device Related

**7.1.1.** Although some newer designs make application quicker and simpler, setup is labor intensive.<sup>33</sup>

**7.1.2** Prolonged stabilization time is required following electrode placement, typically up to 5–10 min, but varies by manufacturer.<sup>9,33,38,84,88</sup>

**7.1.3** While the theoretical basis for mandatory heating of the  $P_{tcO_2}$  electrode in newer TC monitors has not been established,<sup>17,89,90</sup> manufactur-

ers suggest heating the electrode to produce valid results.

**7.1.3.1** Some clinical studies suggest that valid results may be obtained with  $P_{tcCO_2}$  electrodes operated at lower than recommended temperatures or with no heat.<sup>14,27,91,92</sup>

**7.1.4** Improper calibration, trapped air bubbles, leaks in the fixation device, and damaged membranes and their detection may result in misinterpretation of the values and erroneous changes in therapy.<sup>14,21,30,84</sup>

**7.1.4.1** If too much saline or contact gel is applied, a leak may be created between the skin and the fixation device.

### 7.2 Clinical

The following clinical situations may result in falsely elevated or decreased  $P_{tcO_2}$  and  $P_{tcCO_2}$  values:

**7.2.1** Presence of hyperoxemia ( $P_{aO_2} > 100$  mm Hg) (elevated  $P_{tcO_2}$ )<sup>14,86,89</sup>

**7.2.2** The presence of a hypoperfused state (shock, acidosis)<sup>61,93</sup> and vasoactive drug administration<sup>61</sup> may result in decreased  $P_{tcO_2}$  and  $P_{tcCO_2}$ . However, the use of newer TCM devices and placement of the sensor near the carotid artery have improved the correlation between  $P_{aO_2}$  and or  $P_{aCO_2}$  in this clinical situation.<sup>4,25,31,45,55,83,94</sup>

**7.2.3** Improper electrode placement or application (elevated  $P_{tcO_2}$ ; decreased  $P_{tcCO_2}$ )<sup>84</sup>

**7.2.4** Increased thickness or edema of the skin and/or subcutaneous tissue (decreased  $P_{tcO_2}$  and  $P_{tcCO_2}$ )<sup>24,53,61,84,95</sup>

**7.2.5** Increased capillary blood flow induced by movement of the patient, either by self or due to routine care, may increase  $P_{tcO_2}$  and  $P_{tcCO_2}$ .<sup>22,96,97</sup>

**7.2.6** Placement of the sensor site on the distal part of an extremity may result in lower readings, due to vasoconstriction limiting blood flow.<sup>14,15,24</sup>

**7.2.6.1** Some TC monitors allow for the use of the ear area (eg, tragus) as a TC monitoring site. Studies have shown that the ear is an acceptable place for TC monitoring<sup>8,25,27,98</sup>; however, in some cases the ear is not an acceptable place, as it may interfere with a procedure (eg, neurosurgery, maxillofacial surgery).

**7.2.6.2** The ear sensor is less susceptible to detachment with patient movement and does not have to be removed for chest x-rays or other chest imaging procedures.<sup>22,45</sup>

### 7.3 Validation

Arterial blood gas values should be compared to TC readings taken at the time of arterial sampling, in order to validate the TC values. This validation should

be performed initially and periodically, as dictated by the patient's clinical condition.<sup>10,99-102</sup>

**7.3.1** During validation studies in patients with physiologic shunts, the electrode site and arterial sampling site should be on the same side of the shunt when measuring  $P_{tcO_2}$ .<sup>50,84,102</sup> However, recent studies show that  $P_{tcCO_2}$  is not affected by shunts or ventilation-perfusion mismatching, when compared to  $P_{aCO_2}$ .<sup>9,17,103</sup>

**7.3.2** When a discrepancy exists between TC, measured arterial values, and the clinical presentation of the patient, possible causes should be explored before results are reported. Monitoring at alternative sites, recalibration, or equipment replacement may reduce discrepancies. If such steps do not remedy the disparity, TCM results should not be acted upon or recorded in the patient's medical record. Instead, a statement describing the TC use and the corrective action should be included in the patient's medical documentation, and some other mode of monitoring should be established (eg, pulse oximetry, end-tidal CO<sub>2</sub> [ $P_{ETCO_2}$ ] monitoring, arterial blood analysis). The absolute limits that constitute unacceptable discrepancies vary with patient condition and specific device.<sup>92,104,105</sup> Clinical judgment must be exercised.

**7.3.3** When comparing or correlating values for  $P_{CO_2}$ , the  $P_{tcCO_2}$  value is typically higher than  $P_{aCO_2}$ . However, the  $P_{tcCO_2}$  is a good surrogate of the  $P_{aCO_2}$  and sometimes and may provide a better estimate of  $P_{aCO_2}$  than  $P_{ETCO_2}$ .<sup>10,11,27,31,68,74,106-110</sup> Reading an accurate  $P_{CO_2}$  value with a TC monitor requires more time than measuring  $P_{ETCO_2}$ , due to the required period of stabilization of the TCM.<sup>102,111</sup>

**7.3.3.1** Although the acceptable clinical range of agreement for  $P_{tcCO_2}$  is  $\pm 7.5$  mm Hg,<sup>4</sup> the manufacturer's recommendations should be followed.

## TCM 8.0 ASSESSMENT OF NEED

**8.1** When direct measurement of arterial blood is not available or accessible in a timely fashion,  $P_{tcO_2}$  and/or  $P_{tcCO_2}$  measurements may temporarily suffice if the limitations of the data are appreciated.<sup>11</sup>

**8.2** TC blood gas monitoring is appropriate for continuous and prolonged monitoring (eg, during mechanical ventilation, CPAP, and supplemental oxygen administration), but has limitations when used on an intermittent basis.<sup>10,14,49,75</sup>

**8.3**  $P_{tcO_2}$  values can be used for diagnostic purposes, as in the assessment of functional shunts (eg, persistent pulmonary hypertension of the newborn) or per-

sistent fetal circulation, or to determine the response to oxygen challenge in the assessment of congenital heart disease.<sup>39,67,99,100</sup>

## TCM 9.0 ASSESSMENT OF OUTCOME

**9.1** Results should reflect the patient's clinical condition (ie, validate the basis for ordering the monitoring).<sup>15,18,30,97</sup>

**9.2** Documentation of results, therapeutic intervention, and/or clinical decisions based on the TC measurements should be noted in the patient's medical record.

## TCM 10.0 RESOURCES

### 10.1 Equipment

TC monitor, electrodes, calibration gases, and associated supplies. TC monitor should have been validated by the manufacturer, using appropriate quality control procedures and clinical reliability studies.

In order to help assure consistency of care based on TC blood gas readings, the operator should verify:

**10.1.1** High and low limit alarms are set appropriately

**10.1.2** Appropriate electrode temperature is set

**10.1.3** Electrode placement site is appropriate and systematic electrode site change occurs

**10.1.4** Specific manufacturer's recommendations for maintenance, operation, and safety are complied with

**10.1.4.1** Some devices incorporate newer technologies to improve monitoring of oxygen and carbon dioxide by:

**10.1.4.1.1** allowing measurement of  $S_{pO_2}$ ,  $P_{tcO_2}$ , and  $P_{tcCO_2}$ , together or separately, through a miniaturized carbon dioxide tension  $P_{CO_2}/S_{pO_2}$  single sensor that monitors both  $P_{aCO_2}$  and oxygen saturation by pulse oximetry ( $S_{pO_2}$ )<sup>22,25</sup>

**10.1.4.1.2** stabilizing TC values faster through the addition of a heat function

**10.1.4.1.3** showing the clinician, through a relative heating index, how much power the unit is using to warm the site

**10.1.4.1.4** maximizing measurement in low perfusion states through the incorporation of a compensatory heating probe

### 10.2 Personnel

Actively licensed and credentialed respiratory therapists or other credentialed healthcare providers with equivalent training and demonstrated ability to exercise the necessary clinical judgment, to assess the pa-

tient, and to perform the essential tasks of monitor calibration and application.<sup>10</sup>

## TCM 11.0 MONITORING

The monitoring schedule of patient and equipment during TCM should be integrated into the patient assessment and vital signs determinations. Results should be documented in the medical record and should detail the conditions under which the readings were obtained. Additional documentation includes:

- 11.1** The date and time of measurement, TC reading, patient's position, respiratory rate, and activity level
- 11.2**  $F_{IO_2}$  or supplemental oxygen flow, specifying the type of oxygen delivery device
- 11.3** Ventilatory mode and settings
- 11.4** Electrode placement site, electrode temperature, and time of placement
- 11.5** Results of simultaneously obtained  $P_{aO_2}$ ,  $P_{aCO_2}$ , and pH when available
- 11.6** Clinical appearance of the patient, subjective assessment of perfusion, pallor, and skin temperature

## TCM 12.0 FREQUENCY

TC blood gas monitoring should be continuous for development of trending data. Placement for intermittent and short duration measurements (ie, spot checks) is not appropriate.<sup>15,50,112</sup>

## TCM 13.0 INFECTION CONTROL

No special precautions are necessary, but standard precautions (as described by the Centers for Disease Control) are recommended.<sup>113</sup>

- 13.1** The device probe should be cleaned between patient applications, according to manufacturer recommendations.
- 13.2** The external portion of the monitor should be cleaned by methods according to manufacturer recommendations in between patient use.

## TCM 14.0 RECOMMENDATIONS

The following recommendations are made following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)<sup>114</sup> criteria:

- 14.1** Although  $P_{tcCO_2}$  has a good correlation with  $P_{aCO_2}$  and is a reliable method to evaluate plasma CO<sub>2</sub> levels, it is recommended that arterial blood gas values be compared to TC readings taken at the time of arterial sampling, in order to verify the TC values, and periodically as dictated by the patient's clinical condition. (1A)

**14.2** It is suggested that  $P_{tcCO_2}$  may be used in clinical settings where monitoring the adequacy of ventilation is indicated. (2B)

**14.3** It is suggested that  $P_{tcO_2}$  and  $P_{tcCO_2}$  may be used in determining the adequacy of tissue perfusion and monitoring of reperfusion. (2B)

**14.4** It is suggested that TCM should be avoided in the presence of increased thickness or edema of the skin and/or subcutaneous tissue where the sensor is applied. (2B)

**14.5** It is recommended that sites used for a TCM be changed as often as necessary and that they be alternated and observed to avoid thermal injury. Manufacturer recommendations should be followed. (1C)

## TCM 15.0 CPG IDENTIFYING INFORMATION AND AVAILABILITY

### 15.1 Adaptation

Original Publication: Respiratory Care 1994;39(12): 1176–1179.

### 15.2 Guideline Developer

American Association for Respiratory Care Clinical Practice Guidelines Steering Committee.

Ruben D Restrepo MD RRT FAARC (Chair), Department of Respiratory Care, The University of Texas Health Sciences Center at San Antonio, San Antonio, Texas.

Keith R Hirst MSc RRT-NPS (Member), Department of Respiratory Care, Rush University, Chicago, Illinois.

Leonard Wittnebel MSIS RRT (Member), Department of Respiratory Care, The University of Texas Health Sciences Center at San Antonio, San Antonio, Texas

Richard Wettstein MMEd RRT (Member), Department of Respiratory Care, The University of Texas Health Sciences Center at San Antonio, San Antonio, Texas

### 15.3 Source(s) of Funding

None

### 15.4 Financial Disclosures/Conflicts of Interest

No conflicts of interest

## REFERENCES

1. Eberhard P. The design, use, and results of transcutaneous carbon dioxide analysis: current and future directions. Anesth Analg 2007; 105(6 Suppl):S48-S52.
2. Quine D, Stenson BJ. Does the monitoring method influence stability of oxygenation in preterm infants? A randomised crossover study of saturation versus transcutaneous monitoring. Arch Dis Child Fetal Neonatal Ed 2008;93(5):F347-F350.
3. Rüdiger M, Töpfer K, Hammer H, Schmalisch G, Wauer RR. A survey of transcutaneous blood gas monitoring among European neonatal intensive care units. BMC Pediatr 2005;5:30.

4. Bendjelid K, Schutz N, Stotz M, Gerard I, Suter PM, Romand JA. Transcutaneous PCO<sub>2</sub> monitoring in critically ill adults: clinical evaluation of a new sensor. *Crit Care Med* 2005;33(10):2203-2206.
5. Fuke S, Miyamoto K, Ohira H, Ohira M, Odajima N, Nishimura M. Evaluation of transcutaneous CO<sub>2</sub> responses following acute changes in PaCO<sub>2</sub> in healthy subjects. *Respirology* 2009;14(3):436-442.
6. Lagerkvist AL, Sten G, Redfors S, Holmgren D. Repeated blood gas monitoring in healthy children and adolescents by the transcutaneous route. *Pediatr Pulmonol* 2003;35(4):274-279.
7. McVicar J, Eager R. Validation study of a transcutaneous carbon dioxide monitor in patients in the emergency department. *Emerg Med J* 2009;26(5):344-346.
8. Rodriguez P, Lellouche F, Aboab J, Buisson CB, Brochard L. Transcutaneous arterial carbon dioxide pressure monitoring in critically ill adult patients. *Intensive Care Med* 2006;32(2):309-312.
9. Tingay DG, Stewart MJ, Morley CJ. Monitoring of end tidal carbon dioxide and transcutaneous carbon dioxide during neonatal transport. *Arch Dis Child Fetal Neonatal Ed* 2005;90(6):F523-F526.
10. JD, Wilson WR Jr, Meyer DJ. Transcutaneous monitoring of carbon dioxide tension after cardiothoracic surgery in infants and children. *Anesth Analg* 1999;88(3):531-534.
11. Wilson J, Russo P, Russo J, Tobias JD. Noninvasive monitoring of carbon dioxide in infants and children with congenital heart disease: end-tidal versus transcutaneous techniques. *J Intensive Care Med* 2005;20(5):291-295.
12. Sandberg KL, Brynjarsdóttir H, Hjalmarsson O. Transcutaneous blood gas monitoring during neonatal intensive care. *Acta Paediatrica* 2011;100(5):676-679.
13. Gancel PE, Roupie E, Guittet L, Laplume S, Terzi N. Accuracy of a transcutaneous carbon dioxide pressure monitoring device in emergency room patients with acute respiratory failure. *Intensive Care Med* 2011;37(2):348-351.
14. Tobias JD. Transcutaneous carbon dioxide monitoring in infants and children. *Pediatr Anesth* 2009;19(5):434-444.
15. Huch R, Huch A, Albani M, Gabriel M, Schulte F, Wolf H, et al. Transcutaneous PO<sub>2</sub> monitoring in routine management of infants and children with cardiorespiratory problems. *Pediatrics* 1976;57(5):681-690.
16. Lofgren O, Jacobson L. The influence of different electrode temperature on the recorded transcutaneous PO<sub>2</sub> level. *Pediatrics* 1979;64(6):892-897.
17. Dietrich W, Lubbers P. Theoretical basis of the transcutaneous blood gas measurements. *Crit Care Med* 1981;9(10):721-733.
18. Yahav J, Levison H. The validity of the transcutaneous oxygen tension method in children with cardiorespiratory problems. *Am Rev Respir Dis* 1981;124(5):586-587.
19. Monaco F, Nickerson B, McQuitty J. Continuous transcutaneous oxygen and carbon dioxide monitoring in the pediatric ICU. *Crit Care Med* 1982;10(11):765-766.
20. Yip W, Tay J, Wong H, Ho T. Reliability of transcutaneous oxygen monitoring of critically ill children in a general pediatric unit. *Clin Pediatr* 1983;22(6):431-435.
21. Joyce A, Wahr M, Tremper K. Noninvasive oxygen monitoring techniques. *Crit Care Clin* 1995;11(1):199-217.
22. Dullenkopf A, Bernardo SD, Berger F, Fasnacht M, Gerber AC, Weiss M. Evaluation of a new combined SpO<sub>2</sub>/PtcCO<sub>2</sub> sensor in anaesthetized paediatric patients. *Paediatr Anaesth* 2003;13(9):777-784.
23. Fruchter O, Carmi U, Ingenito EP, Refaeli Y, Kramer MR. Transcutaneous carbon dioxide in severe COPD patients during bronchoscopic lung volume reduction. *Respir Med* 2011;105(4):602-607.
24. Nishiyama T, Nakamura S, Yamashita K. Comparison of the transcutaneous oxygen and carbon dioxide tension in different electrode locations during general anaesthesia. *Eur J Anaesthesiol* 2006;23(12):1049-1054.
25. Senn O, Clarenbach CF, Kaplan V, Maggiorini M, Bloch KE. Monitoring carbon dioxide tension and arterial oxygen saturation by a single earlobe sensor in patients with critical illness or sleep apnea. *Chest* 2005;128(3):1291-1296.
26. Roediger R, Beck-Schimmer B, Theusinger OM, Rusch D, Seifert B, Spahn DR, et al. The revised digital transcutaneous PCO<sub>2</sub>/SpO<sub>2</sub> ear sensor is a reliable noninvasive monitoring tool in patients after cardiac surgery. *J Cardiothorac Vasc Anesth* 2011;25(2):243-9.
27. Fanconi S, Tschupp A, Molinari L. Long-term transcutaneous monitoring of oxygen tension and carbon dioxide at 42 degrees C in critically ill neonates: improved performance of the tCO<sub>2</sub> monitor with topical metabolic inhibition. *Eur J Pediatr* 1996;155(12):1043-1046.
28. Vallée F, Mateo J, Dubreuil G, Poussant T, Tachon G, Ouanoounou I, Payen D. Cutaneous ear lobe PCO<sub>2</sub> at 37 degrees C to evaluate microperfusion in patients with septic shock. *Chest* 2010;138(5):1062-1070.
29. Molloy EJ, Deakins K. Are carbon dioxide detectors useful in neonates? *Arch Dis Child Fetal Neonatal Ed* 2006;91:F295-F298.
30. O'Connor TM, Grueber R. Transcutaneous measurement of carbon dioxide tension during long-distance transport of neonates receiving mechanical ventilation. *J Perinatol* 1998;18(3):189-192.
31. Berkenbosch JW, Lam J, Burd RS, Tobias JD. Noninvasive monitoring of carbon dioxide during mechanical ventilation in older children: end-tidal versus transcutaneous techniques. *Anesth Analg* 2001;92(6):1427-1431.
32. Tobias JD, Meyer DJ. Noninvasive monitoring of carbon dioxide during respiratory failure in toddlers and infants: end-tidal versus transcutaneous carbon dioxide. *Anesth Analg* 1997;85(1):55-58.
33. Hazenberg A, Zijlstra JG, Kerstjens HA, Wijkstra PJ. Validation of a transcutaneous CO<sub>2</sub> monitor in adult patients with chronic respiratory failure. *Respiration* 2011;81(3):242-246.
34. Berkenbosch JW, Tobias JD. Transcutaneous carbon dioxide monitoring during high-frequency oscillatory ventilation in infants and children. *Crit Care Med* 2002;30(5):1024-1027.
35. Simon M, Gottschall R, Gugel M, Fritz H, Mohr S, Klein U. Comparison of transcutaneous and endtidal CO<sub>2</sub>-monitoring for rigid bronchoscopy during high-frequency jet ventilation. *Acta Anaesthesiol Scand* 2003;47(7):861-867.
36. Tobias J. Noninvasive monitoring of carbon dioxide during respiratory failure in toddlers and infants: end tidal versus transcutaneous carbon dioxide. *Anesth Analg* 1997;85(1):55-58.
37. Maniscalco M, Zedda A, Faraone S, Carratu P, Sofia M. Evaluation of a transcutaneous carbon dioxide monitor in severe obesity. *Intensive Care Med* 2008;34(7):1340-1344.
38. Storre JH, Magnet FS, Dreher M, Windisch W. Transcutaneous monitoring as a replacement for arterial PCO<sub>2</sub> monitoring during nocturnal non-invasive ventilation. *Respir Med* 2011;105(1):143-150.
39. Storre JH, Steurer B, Kabitz HJ, Dreher M, Windisch W. Transcutaneous PCO<sub>2</sub> monitoring during initiation of noninvasive ventilation. *Chest* 2007;132(6):1810-1816.
40. Holmgren D, Redfors S, Solymar L. Transcutaneous-PO<sub>2</sub> monitoring for detection of exercise-induced right-to-left shunts in children with congenital heart defects: a case report. *Acta Paediatr* 2001;90(7):816-818.
41. Chhajed PN, Rajasekaran R, Kaegi B, Chhajed TP, Pflimlin E, Leuppi J, et al. Measurement of combined oximetry and cutaneous capnography during flexible bronchoscopy. *Eur Respir J* 2006;28(2):386-390.
42. Evans EN, Ganeshalingam K, Ebden P. Changes in oxygen saturation and transcutaneous carbon dioxide and oxygen levels in pa-

- tients undergoing fibreoptic bronchoscopy. *Respir Med* 1998;92(5):739-742.
43. Tatevossian R, Wo C, Velmahos G, Demetriades D, Shoemaker W. Transcutaneous oxygen and CO<sub>2</sub> as early warning of tissue hypoxia and hemodynamic shock in critically ill emergency patients. *Crit Care Med* 2000;28(7):2248-2253.
  44. Heuss LT, Chhajed PN, Schnieper P, Hirt T, Beglinger C. Combined pulse oximetry/cutaneous carbon dioxide tension monitoring during colonoscopies: pilot study with a smart ear clip. *Digestion* 2004;70(3):152-158.
  45. Pellicer A, Valverde E, Elorza MD, Madero R, Gayá F, Quero J, Cabañas F. Cardiovascular support for low birth weight infants and cerebral hemodynamics: a randomized, blinded, clinical trial. *Pediatrics* 2005;115(6):1501-1512.
  46. Kopka A, Wallace E, Reilly G, Binning A. Observational study of perioperative PtcCO<sub>2</sub> and SpO<sub>2</sub> in non-ventilated patients receiving epidural infusion or patient-controlled analgesia using a single ear-lobe monitor (TOSCA). *Br J Anaesth* 2007;99(4):567-571.
  47. McCormack JG, Kelly KP, Wedgwood J, Lyon R. The effects of different analgesic regimens on transcutaneous CO<sub>2</sub> after major surgery. *Anesthesia* 2008;63(8):814-821.
  48. Nelson DB, Freeman ML, Silvis SE, Cass OW, Yakshe PN, Vennes J, et al. A randomized, controlled trial of transcutaneous carbon dioxide monitoring during ERCP. *Gastrointest Endosc* 2000;51(3):288-295.
  49. Qingsheng Xue, Xiaowen Wu, Jue Jin, Buwei Yu, Minhua Zheng. Transcutaneous carbon dioxide monitoring accurately predicts arterial carbon dioxide partial pressure in patients undergoing prolonged laparoscopic surgery. *Anesth Analg* 2010;111:417-420.
  50. Kirk VG, Batuyong ED, Bohn SG. Transcutaneous carbon dioxide monitoring and capnography during pediatric polysomnography. *Sleep* 2006;29(12):1601-1608.
  51. Lucey JF. Clinical uses of transcutaneous oxygen monitoring. *Adv Pediatr* 1981;28:27-56.
  52. Randerath WJ, Stieglitz S, Galetke W, Anduleit N, Treml M, Schäfer T. Evaluation of a system for transcutaneous long-term capnometry. *Respiration* 2010;80(2):139-145.
  53. Rauhala E, Himanen SL, Saastamoinen A, Polo O. Prolonged spiking in the Emfit sensor in patients with sleep-disordered breathing is characterized by increase in transcutaneous carbon dioxide. *Physiol Meas* 2007;28(10):1163-1173.
  54. Mok J, Pintar M, Benson L, McLaughlin FJ, Levison H. Evaluation of noninvasive measurements of oxygenation in stable infants. *Crit Care Med* 1986;14(11):960-963.
  55. Virkki A, Polo O, Saaresranta T, Laapotti-Salo A, Gyllenberg M, Aittokallio T. Overnight features of transcutaneous carbon dioxide measurement as predictors of metabolic status. *Artif Intell Med* 2008;42(1):55-65.
  56. Carter B, Hochmann M, Osborne A, Nisbet A, Campbell N. A comparison of two transcutaneous monitors for the measurement of arterial PO<sub>2</sub> and PCO<sub>2</sub> in neonates. *Anaesth Intensive Care* 1995;23(6):708-714.
  57. Holmgren D, Redfors S, Wennergren G, Sten G. Histamine provocation in young, awake children with bronchial asthma, using a fall in oxygenation as the only indicator of a bronchial reaction. *Acta Paediatr* 1999;88(5):545-549.
  58. Klug B, Bisgaard H. Measurement of lung function in awake 2-4-year-old asthmatic children during methacholine challenge and acute asthma: a comparison of the impulse oscillation technique, the interrupter technique, and transcutaneous measurement of oxygen versus whole-body plethysmography. *Pediatr Pulmonol* 1996;21(5):290-300.
  59. Stege G, van den Elshout FJ, Heijdra YF, van de Ven MJ, Dekhuijzen PN, Vos PJ. Accuracy of transcutaneous carbon dioxide tension measurements during cardiopulmonary exercise testing. *Respiration* 2009;78(2):147-153.
  60. McBride ME, Berkenbosch JW, Tobias JD. Transcutaneous carbon dioxide monitoring during diabetic ketoacidosis in children and adolescents. *Paediatr Anaesth* 2004;14(2):167-171.
  61. Lang CJ. Apnea testing guided by continuous transcutaneous monitoring of partial pressure of carbon dioxide. *Crit Care Med* 1998;26(5):868-872.
  62. Martin M, Matthew Martina CB, Bayard D, Demetriades D, Salim A, Gertz R, et al. Continuous noninvasive monitoring of cardiac performance and tissue perfusion in pediatric trauma patients. *J Pediatr Surg* 2005;40:1957-1963.
  63. Shoemaker WC, Wo CC, Demetriades D, Belzberg H, Asensio JA, Cornwell EE, et al. Early physiologic patterns in acute illness and accidents: toward a concept of circulatory dysfunction and shock based on invasive and noninvasive hemodynamic monitoring. *New Horiz* 1996;4(4):395-412.
  64. Shoemaker WC, Wo CC, Lu K, Chien LC, Rhee P, Bayard D, et al. Noninvasive hemodynamic monitoring for combat casualties. *Mil Med* 2006;171(9):813-820.
  65. Sugimoto I, Ohta T, Ishibashi H, Iwata H, Kawanishi J, Yamada T, et al. Transcutaneous carbon dioxide tension for the evaluation of limb ischemia. *Surg Today* 2009;39(1):9-13.
  66. Tatevossian RG, Shoemaker WC, Wo CC, Dang AB, Velmahos GC, Demetriades D. Noninvasive hemodynamic monitoring for early warning of adult respiratory distress syndrome in trauma patients. *J Crit Care* 2000;15(4):151-159.
  67. Yu M, Morita SY, Daniel SR, Chapital A, Waxman K, Severino R. Transcutaneous pressure of oxygen: a noninvasive and early detector of peripheral shock and outcome. *Shock* 2006;26(5):450-456.
  68. Drummond KJ, Fearnside MR, Chee A. Transcutaneous carbon dioxide measurement after craniotomy in spontaneously breathing patients. *Neurosurg* 1997;41(2):361-365.
  69. Xue Q, Wu X, Jin J, Yu B, Zheng M. Transcutaneous carbon dioxide monitoring accurately predicts arterial carbon dioxide partial pressure in patients undergoing prolonged laparoscopic surgery. *Anesth Analg* 2010;111(2):417-420.
  70. Miyazaki H, Umezaki T, Yamashita H, Yamamoto T, Komiyama S. Transcutaneous PCO<sub>2</sub> monitoring with hyperventilation during phonation in vocal cord paralysis. *Auris Nasus Larynx* 2002;29(3):277-282.
  71. Miyazaki H, Yamashita H, Masuda T, Yamamoto T, Komiyama S. Transcutaneous PCO<sub>2</sub> monitoring in the evaluation of hyperventilation of patients with recurrent nerve paralysis. *Eur Arch Otorhinolaryngol* 1999;256(Suppl 1):S47-S50.
  72. Török SS, Leuppi JD, Baty F, Prashant MT, Chhajed N. Combined oximetry-cutaneous capnography in patients assessed for long-term oxygen therapy. *Chest* 2008;133:1421-1425.
  73. Martin RJ. Transcutaneous monitoring: instrumentation and clinical applications. *Respir Care* 1990;35(6):577-583.
  74. Stausholm K, Rosenberg-Adamsen S, Edvardsen L, Kehlet H, Rosenberg J. Validation of pulse oximetry for monitoring of hypoxaemic episodes in the late postoperative period. *Br J Anaesth* 1997;78(1):86-87.
  75. Urbano J, Cruzado V, Lopez-Herce J, del Castillo J, Bellon JM, Carrillo A. Accuracy of three transcutaneous carbon dioxide monitors in critically ill children. *Pediatr Pulmonol* 2010;45(5):481-486.
  76. Weaver LK. Transcutaneous oxygen and carbon dioxide tensions compared to arterial blood gases in normals. *Respir Care* 2007;52(11):1490-1496.
  77. Severinghaus JW. Transcutaneous blood gas analysis. *Respir Care* 1982;27(2):152-159.

78. Chakravarthy M, Narayan S, Govindarajan R, Jawali V, Rajeev S. Weaning mechanical ventilation after off-pump coronary artery bypass graft procedures directed by noninvasive gas measurements. *J Cardiothorac Vasc Anesth* 2010;24(3):451-455.
79. Johnson DC, Batool S, Dalbec R. Transcutaneous carbon dioxide pressure monitoring in a specialized weaning unit. *Respir Care* 2008;53(8):1042-1047.
80. Rodrigues LM, Pinto PC, Leal A. Transcutaneous flow related variables measured in vivo: the effects of gender. *BMC Dermatol* 2001;1:4.
81. Ruangsetakit C, Chinsakchai K, Mahawongkajit P, Wongwanit C, Mutirangura P. Transcutaneous oxygen tension: a useful predictor of ulcer healing in critical limb ischaemia. *J Wound Care* 2010; 19(5):202-206.
82. Chiriano J, Bianchi C, Teruya TH, Mills B, Bishop V, Abou-Zamzam AM. Management of lower extremity wounds in patients with peripheral arterial disease: a stratified conservative approach. *Ann Vasc Surg* 2010;24(8):1110-1116.
83. Martin RJ, Robertson SS, Hopple MM. Relationship between transcutaneous and arterial oxygen tension in sick neonates during mild hyperoxemia. *Crit Care Med* 1982;10(10):670-672.
84. Steurer J, Hoffmann U, Dur P, Russi E, Vetter W. Changes in arterial and transcutaneous oxygen and carbon dioxide tensions during and after voluntary hyperventilation. *Respiration* 1997;64(3): 200-205.
85. Mike V, Ross GS. Doctors and the health industry: a case study of transcutaneous oxygen monitoring in neonatal intensive care. *Soc Sci Med* 1996;42(9):1247-1258.
86. Lucia LD, Aliwalas M, Noble L, Nesbitt K, Fallah S, Shah V, Shah P. Agreement of carbon dioxide levels measured by arterial, transcutaneous, and end tidal methods in preterm infants  $\leq$  28 weeks gestation. *J Perinatol* 2005;25(1):26-29.
87. Poets CF, Southall DP. Noninvasive monitoring of oxygenation in infants and children: practical considerations and areas of concern. *Pediatrics* 1994;93(5):737-746.
88. Kesten S, Chapman KR, Rebuck AS. Response characteristics of a dual transcutaneous oxygen/carbon dioxide monitoring system. *Chest* 1991;99(5):1211-1215.
89. McLellan PA, Goldstein RS, Ramcharan V, Rebuck AS. Transcutaneous carbon dioxide monitoring. *Am Rev of Respir Dis* 1981; 124(2):199-201.
90. Talbot A, Neuman MR, Saidel GM, Jacobsen E. Dynamic model of oxygen transport for transcutaneous PO<sub>2</sub> analysis. *Ann Biomed Eng* 1996;24(2):294-304.
91. Rudiger M, Topfer K, Hammer H, Schmalisch G, Wauer RR. A survey of transcutaneous blood gas monitoring among European neonatal intensive care units. *BMC Pediatr* 2005;5:30.
92. Marsden D, Chiu MC, Paky F, Helms P. Transcutaneous oxygen and carbon dioxide monitoring in intensive care. *Arch Dis Child* 1985;60(12):1158-1161.
93. Versmold HT, Linderkamp O, Holzmann M, Strohhacker I, Riegel K. Transcutaneous monitoring of PO<sub>2</sub> in newborn infants: where are the limits? Influence of blood pressure, blood volume, blood flow, viscosity, and acid base state. *Birth Defects Orig Artic Ser* 1979;15(4):285-294.
94. Vivien B, Marmion F, Roche S, Devilliers C, Langeron O, Coriat P, et al. An evaluation of transcutaneous carbon dioxide partial pressure monitoring during apnea testing in brain-dead patients. *Anesthesiology* 2006;104(4):701-707.
95. Nishiguchi BK, Yu M, Suetsugu A, Jiang C, Takiguchi SA, Takanishi DM Jr. Determination of reference ranges for transcutaneous oxygen and carbon dioxide tension and the oxygen challenge test in healthy and morbidly obese subjects. *J Surg Res* 2008; 150(2):204-211.
96. Planes C, Leroy M, Foray E, Raffestin B. Arterial blood gases during exercise: validity of transcutaneous measurements. *Arch Phys Med Rehabil* 2001;82(12):1686-1691.
97. Verderber A, Gallagher KJ, Severino R. The effect of nursing interventions on transcutaneous oxygen and carbon dioxide tensions. *West J Nurs Res* 1995;17(1):76-90.
98. Bernet-Buettiker V, Ugarte MJ, Frey B, Hug MI, Baenziger O, Weiss M. Evaluation of a new combined transcutaneous measurement of PCO<sub>2</sub>/pulse oximetry oxygen saturation ear sensor in newborn patients. *Pediatrics* 2004;115(1):e64-e68.
99. Rosner V, Hannhart B, Chabot F, Polu JM. Validity of transcutaneous oxygen/carbon dioxide pressure measurement in the monitoring of mechanical ventilation in stable chronic respiratory failure. *Eur Respir J* 1999;13(5):1044-1047.
100. Brouillette RT, Waxman DH. Evaluation of the newborn's blood gas status. *Clin Chem* 1997;43(1):215-221.
101. Cassady G. Transcutaneous monitoring in the newborn infant. *J Pediatr* 1983;103(6):837-848.
102. Pearlman SA, Maisels MJ. Preductal and postductal transcutaneous oxygen tension measurements in premature newborns with hyaline membrane disease. *Pediatrics* 1989;83(1):98-100.
103. Tateishi K, Yamanouchi I. Noninvasive transcutaneous oxygen pressure diagnosis of reversed ductal shunts in cyanotic heart disease. *Pediatrics* 1980;66(1):22-25.
104. Bolliger D, Steiner LA, Kasper J, Aziz OA, Filipovic M, Seeberger MD. The accuracy of non-invasive carbon dioxide monitoring: a clinical evaluation of two transcutaneous systems. *Anaesthesia* 2007; 62(4):394-399.
105. Wollburg E, Roth WT, Kim S. End-tidal versus transcutaneous measurement of PCO<sub>2</sub> during voluntary hypo- and hyperventilation. *Int J Psychophysiol* 2009;71(2):103-108.
106. Casati A, Squicciarini G, Malagutti G, Baciarello M, Putzu M, Fanelli A. Transcutaneous monitoring of partial pressure of carbon dioxide in the elderly patient: a prospective, clinical comparison with end-tidal monitoring. *J Clin Anesth* 2006;18(6):436-440.
107. Hirabayashi M, Fujiwara C, Ohtani N, Kagawa S, Kamide M. Transcutaneous PCO<sub>2</sub> monitors are more accurate than end-tidal PCO<sub>2</sub> monitors. *J Anesth* 2009;23(2):198-202.
108. Lopez E, Grabar S, Barbier A, Krauss B, Jarreau PH, Moriette G. Detection of carbon dioxide thresholds using low-flow sidestream capnography in ventilated preterm infants. *Intensive Care Med* 2009; 35(11):1942-1949.
109. McBride DS Jr, Johnson JO, Tobias JD. Noninvasive carbon dioxide monitoring during neurosurgical procedures in adults: end-tidal versus transcutaneous techniques. *South Med J* 2002;95(8):870-874.
110. Nosovitch MA, Johnson JO, Tobias JD. Noninvasive intraoperative monitoring of carbon dioxide in children: endtidal versus transcutaneous techniques. *Paediatr Anaesth* 2002;12(1):48-52.
111. Stein N, Schneeweiss A, Eckmann C, Roth-Isigkeit A, Hüppé M, Gehring H. An evaluation of a transcutaneous and an end-tidal capnometer for noninvasive monitoring of spontaneously breathing patients. *Respir Care* 2006;51(10):1162-1166.
112. Rauch DA, Ewig J, Benoit P, Clark E, Bijur P. Exploring intermittent transcutaneous CO<sub>2</sub> monitoring. *Crit Care Med* 1999;27(11): 2358-2360.
113. Jensen PA, Lambert LA, Iademarco MF, Ridzon R; Centers for Disease Control and Prevention. Guidelines for preventing the transmission of *Mycobacterium tuberculosis* in health-care settings, 2005. *MMWR Recomm Rep* 2005;54(RR-17):1-141.
114. Restrepo RD. AARC Clinical Practice Guidelines: from "reference-based" to "evidence-based" (editorial). *Respir Care* 2010;55(6): 787-789.